VK2735 vs Tirzepatide
VK2735 vs Tirzepatide: two dual GLP-1/GIP agonists on results, the oral option, and availability.
The verdict
Same mechanism, very different stage. Both hit GLP-1 and GIP, but Tirzepatide is FDA-approved, proven, and available now, while VK2735 is still investigational (the injectable is in Phase 3, the oral form is heading into Phase 3 around late 2026, with readouts not before 2027). The reason VK2735 gets attention is its oral form, a once-daily pill that landed near injectable results in trials. If you want something real today, Tirzepatide is the only one of the two you can actually get. VK2735 is a watch-this-space, not a current option.
VK2735 is an experimental weight-loss drug from Viking Therapeutics. It works on two gut-hormone receptors (GLP-1 and GIP) to cut appetite, the same combo as Tirzepatide. The notable part is the pill version: in early trials a once-daily tablet got close to the results of the injection. It is still in testing and not approved.
Tirzepatide is the prescription weight-loss drug sold as Mounjaro (diabetes) or Zepbound (weight loss). It hits two appetite-control receptors at once. Most users lose 15-20% of body weight over several months. One injection per week.
Which one should you pick?
Pick VK2735 if people following the oral-glp-1 race who want a needle-free option or users tracking next-generation weight-loss compounds before approval.
Pick Tirzepatide if users who couldn't tolerate semaglutide or metabolic-syndrome adults under provider guidance.
Still torn between VK2735 and Tirzepatide?
The AI Coach reads both, asks about your goal and experience, and tells you which one actually fits — plus how to dose and stack it. Free.